Ning Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ning Dong has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Julio C. Chavez
Mayo Clinic
3 shared publications Leidy Isenalumhe
Department of Malignant Hematology Moffitt Cancer Center Tampa Florida USA
3 shared publicationsCeleste Bello
Department of Malignant Hematology Moffitt Cancer Center Tampa Florida USA
2 shared publicationsHailing Zhang
University of South Florida Morsani College of Medicine Tampa Florida USA
2 shared publicationsJinming Song
University of South Florida Morsani College of Medicine Tampa Florida USA
2 shared publications- Ling Zhang
Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2 shared publications
Latest Publications
- 3 August 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70235
A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T‐Cell Lymphoma
Mature T‐cell lymphomas (TCL) are aggressive malignancies with limited effective therapies. Duvelisib (DUV), a dual inhibitor of PI3K‐δ and PI3K‐γ, has shown promising activity in TCL. Azacitidine (AZA), a hypomethylating agent, has demonstrated efficacy in TCL and may enhance the activity of PI3K inhibitors through epigenetic modulation and immune regulation. We conducted a phase I, open‐label, 3 + 3 dose‐escalation study of oral duvelisib in combination with oral azacitidine (BMS‐986345) in patients with relapsed or refractory TCL. The primary objective was to identify the maximum tolerated dose (MTD) of the combination. Fourteen patients ( N = 14) were enrolled with a median age of 63.5 years. The median number of prior therapies was two. Grade ≥ 3 toxicities, expressed for the full treated population ( N = 14), included neutropenia (29%), anemia (21%), AST elevation (21%), ALT elevation (14%), thrombocytopenia (14%), and leukocytosis (14%). Most adverse events were grade 1–2 and manageable. The ORR was 46% ( N = 6), with 31% ( N = 4) complete responses (CR) and 15% ( N = 2) partial responses (PR). All four evaluable patients with a T‐follicular‐helper (TFH) phenotype achieved CR, a hypothesis‐generating observation given the small denominator. Median PFS was 2.2 months (95% CI 1.8–NE) and median OS 10.2 months (95% CI 6.3–NE); however, median duration of response was not reached, and three responders were censored at the time of allogeneic transplant. On‐treatment suppression of AKT phosphorylation was enhanced during combined therapy. Duvelisib plus oral azacitidine had a manageable safety profile and encouraging activity, particularly in the TFH subtype, where responses were deep and enabled a bridge to allogeneic transplant. Randomized evaluation focused on the TFH subtype is warranted. Trial Registration: NCT05065866
- 3 August 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (5) , e70235
A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T‐Cell Lymphoma
Mature T‐cell lymphomas (TCL) are aggressive malignancies with limited effective therapies. Duvelisib (DUV), a dual inhibitor of PI3K‐δ and PI3K‐γ, has shown promising activity in TCL. Azacitidine (AZA), a hypomethylating agent, has demonstrated efficacy in TCL and may enhance the activity of PI3K inhibitors through epigenetic modulation and immune regulation. We conducted a phase I, open‐label, 3 + 3 dose‐escalation study of oral duvelisib in combination with oral azacitidine (BMS‐986345) in patients with relapsed or refractory TCL. The primary objective was to identify the maximum tolerated dose (MTD) of the combination. Fourteen patients ( N = 14) were enrolled with a median age of 63.5 years. The median number of prior therapies was two. Grade ≥ 3 toxicities, expressed for the full treated population ( N = 14), included neutropenia (29%), anemia (21%), AST elevation (21%), ALT elevation (14%), thrombocytopenia (14%), and leukocytosis (14%). Most adverse events were grade 1–2 and manageable. The ORR was 46% ( N = 6), with 31% ( N = 4) complete responses (CR) and 15% ( N = 2) partial responses (PR). All four evaluable patients with a T‐follicular‐helper (TFH) phenotype achieved CR, a hypothesis‐generating observation given the small denominator. Median PFS was 2.2 months (95% CI 1.8–NE) and median OS 10.2 months (95% CI 6.3–NE); however, median duration of response was not reached, and three responders were censored at the time of allogeneic transplant. On‐treatment suppression of AKT phosphorylation was enhanced during combined therapy. Duvelisib plus oral azacitidine had a manageable safety profile and encouraging activity, particularly in the TFH subtype, where responses were deep and enabled a bridge to allogeneic transplant. Randomized evaluation focused on the TFH subtype is warranted. Trial Registration: NCT05065866
- Open Access
- 5 March 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (6) , 349.e1-349.e8
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma
- 5 March 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (6) , 349.e1-349.e8
Open AccessOutcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma
- 1 June 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (6) , e414-e426
The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia
- 1 June 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (6) , e414-e426
The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia
- 5 April 2021
- Published by Wiley in American Journal of Hematology
- Vol. 96 (7) , 772-780
Large granular lymphocytic leukemia – A retrospective study of 319 cases
Large granular lymphocytic leukemia (LGLL) is a rare hematological malignancy that arises from cytotoxic T lymphocytes (T‐LGLL) in 85% of cases and natural killer (NK) cells in the rest. A significant knowledge gap exists regarding the pathogenesis, treatment choices, and prognostic factors of LGLL. We report a cohort of 319 consecutive LGLL patients who presented to our cancer center between 2001 and 2020. A total of 295 patients with T‐LGLL and 24 with chronic NK‐cell lymphoproliferative disorder (CLPD‐NK) were identified. The median age was 65 years (range, 17–90 years). Eighty‐three patients (26.0%) had autoimmune diseases. A total of 119 patients (37.3%) had coexisting malignancies, 66 (20.7%) had solid tumors, and 59 (18.5%) had hematological malignancies. Most coexisting malignancies were diagnosed before the diagnosis of LGLL. Treatment was needed for 57% of patients. Methotrexate (MTX), cyclophosphamide (Cy), and cyclosporine A (CSA) were most used and had similar response rates between 61.5%–74.4%. Cy produced more complete responses (32.3%) compared to MTX and CSA (15.7% and 23.1%, respectively). Thrombocytopenia, splenomegaly, and female gender (after controlling for autoimmune diseases) were associated with decreased response rates to MTX, CSA, or Cy. Autoimmune diseases were associated with increased response rates. Thrombocytopenia was an independent risk factor for worse survival.
- 5 April 2021
- Published by Wiley in American Journal of Hematology
- Vol. 96 (7) , 772-780
Large granular lymphocytic leukemia – A retrospective study of 319 cases
Large granular lymphocytic leukemia (LGLL) is a rare hematological malignancy that arises from cytotoxic T lymphocytes (T‐LGLL) in 85% of cases and natural killer (NK) cells in the rest. A significant knowledge gap exists regarding the pathogenesis, treatment choices, and prognostic factors of LGLL. We report a cohort of 319 consecutive LGLL patients who presented to our cancer center between 2001 and 2020. A total of 295 patients with T‐LGLL and 24 with chronic NK‐cell lymphoproliferative disorder (CLPD‐NK) were identified. The median age was 65 years (range, 17–90 years). Eighty‐three patients (26.0%) had autoimmune diseases. A total of 119 patients (37.3%) had coexisting malignancies, 66 (20.7%) had solid tumors, and 59 (18.5%) had hematological malignancies. Most coexisting malignancies were diagnosed before the diagnosis of LGLL. Treatment was needed for 57% of patients. Methotrexate (MTX), cyclophosphamide (Cy), and cyclosporine A (CSA) were most used and had similar response rates between 61.5%–74.4%. Cy produced more complete responses (32.3%) compared to MTX and CSA (15.7% and 23.1%, respectively). Thrombocytopenia, splenomegaly, and female gender (after controlling for autoimmune diseases) were associated with decreased response rates to MTX, CSA, or Cy. Autoimmune diseases were associated with increased response rates. Thrombocytopenia was an independent risk factor for worse survival.